Neurosense Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 |
|---|---|---|
Revenue | $0 | $0 |
EBITDA | -2,107 | |
EBIT | -1,771 | -2,112 |
Net Income | -1,801 | -2,148 |
Net Change In Cash | 0 | 0 |
Free Cash Flow | ||
Cash | 3,378 | 344 |
Basic Shares | 23,228 | 19,809 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -22 | -97 | -89 | -3 |
EBITDA | -9,877 | -9,638 | -12,229 | -2,884 |
EBIT | -9,899 | -9,659 | -12,318 | -2,887 |
Net Income | -10,210 | -10,107 | -12,340 | -4,041 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -10,138 | -8,383 | -7,656 | -1,556 |
Cash | 3,378 | 2,640 | 3,543 | 11,063 |
Basic Shares | 18,602 | 13,640 | 11,505 | 10,856 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.13 |
2025-03-31 | -$0.06 |
2024-12-31 | -$0.06 |
